IPC분류정보
국가/구분 |
United States(US) Patent
공개
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0486145
(2002-08-07)
|
공개번호 |
US-0234674
(2004-11-25)
|
우선권정보 |
DE-0038929 (2001-08-08) |
국제출원번호 |
PCT/EP02/08838
(2002-08-07)
|
발명자
/ 주소 |
- Eich, Jurgen
- Haffner, Thomas
- Goerke, Thomas
- Schneider, Werner
|
대리인 / 주소 |
Scully Scott Murphy & Presser
|
인용정보 |
피인용 횟수 :
0 인용 특허 :
0 |
초록
▼
The invention relates to artichoke leaf extracts ( Cynarae folium ) that are characterized by defined absolute percentages and relative inherent percentages of typical constituents of artichoke leaves such as caffeoyl quinic acids and flavonoids The activity spectrum of the inventive leaf extracts
The invention relates to artichoke leaf extracts ( Cynarae folium ) that are characterized by defined absolute percentages and relative inherent percentages of typical constituents of artichoke leaves such as caffeoyl quinic acids and flavonoids The activity spectrum of the inventive leaf extracts is substantially different from known artichoke leaf extracts, said inventive leaf extracts also being different from each other. The invention also relates to methods for producing the extracts and to fields of application thereof.
대표청구항
▼
1 . Extract of artichoke leaves ( Cynarae folium ) containing:a total CQA content of mono-CQA and di-CQA of at least 6%, preferably 10 to 50%, relative to the total quantity of the extract,a flavonoid content of at least 3%, preferred 4%, preferably 7 to 30%, relative to the total quantity of the e
1 . Extract of artichoke leaves ( Cynarae folium ) containing:a total CQA content of mono-CQA and di-CQA of at least 6%, preferably 10 to 50%, relative to the total quantity of the extract,a flavonoid content of at least 3%, preferred 4%, preferably 7 to 30%, relative to the total quantity of the extract. 2 . Extract according to claim 1 having a content of mono-CQA of less than 30%, preferably 3 to 30%, particularly preferred 10 to 30%, relative to the total CQA content. 3 . Extract according to claim 1 or 2 having a ratio of mono-CQA content to flavonoid content of less than 1. 4 . Method for the production of an extract of artichoke leaves ( Cynarae folium ) according to claims 1 to 3, comprising the steps of:liquid-liquid-extraction of a primary extract from fresh or dried artichoke leaves obtained by extraction with water or by extraction with an organic solvent from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a non-aqueous organic solvent from the series of alcohols, ketones, esters, ethers, aromatics or mixture of these compounds, andobtaining the organic phase 5 . Method according to claim 4, whereby the organic solvent for the extraction of the primary extract is a mixture of 2-butanol and ethyl acetate. 6 . Method according to claim 4 or 5 comprising the preceding steps of:concentrating the primary extract volume or adding water to the primary extract until the extract contains more than 50% water.washing the extract with a non-polar, water-immiscible solvent, preferably one from the series of alkanes, alkenes, ethers, esters or chlorinated hydrocarbons; separating and disposing of the organic phase. 7 . Extract of artichoke leaves ( Cynarae folium ) containing:a total CQA content of mono-CQA and di-CQA of at least 1%, preferably 2 to 15%, relative to the total quantity of the extract,a flavonoid content of a maximum of 2%, preferably 0.02 to 1.5%, relative to the total quantity of the extract, a content of mono-CQA of at least 70%, preferably at least 75%, relative to the total CQA content. 8 . Extract according to claim 7 having a ratio of mono-CQA content to flavonoid content of between 4 and 35, preferably 5 to 35. 9 . Method for the production of an extract of artichoke leaves ( Cynarae folium ) according to claim 7 or 8 comprising the steps of:liquid-liquid-extraction of a primary extract from fresh or dried artichoke leaves obtained by extraction with water or by extraction with an organic solvent from the series of alcohols, ketones, esters, ethers, preferably methanol, ethanol or mixtures of these compounds with water, with a non-aqueous organic solvent from the series of alcohols, ketones, esters, ethers, aromatics or mixture of these compounds, andobtaining the aqueous phase. 10 . Method according to claim 9, whereby the organic solvent for the extraction of the primary extract is a mixture of 2-butanol and ethyl acetate. 11 . Method according to claim 9 or 10 comprising the preceding steps of:concentrating the primary extract volume or adding water to the primary extract until the extract contains more than 50% water,washing the extract with a non-polar, water-immiscible solvent, preferably one from the series of alkanes, alkenes, ethers, esters or chlorinated hydrocarbons; separating and disposing of the organic phase. 12 . Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the production of medicinal products. 13 . Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the production of foodstuffs. 14 . Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the production of dietetic foods. 15 . Use of the extracts according to one of claims 1 to 3 and 7 to 8 for the production of cosmetics. 16 . Use of the extracts according to one of claims 1 to 3 for the production of a preparation according to claims 12 to 15 having an anti-oxidative, cell- and organ-protecting action. 17 . Use of the extract according to one of claims 1 to 3 for the production of a preparation according to claims 12 to 15 for the treatment and prophylaxis of hypercholesterolaemia and hyperlipidaemia. 18 . Use of the extract according to one of claims 1 to 3 for the production of a preparation according to claims 12 to 15 for the treatment and prophylaxis of cardiovascular diseases and arteriosclerosis. 19 . Use of the extract according to one of claims 1 to 3 for the production of a preparation according to claims 12 to 15 for the treatment and prophylaxis of dementia. 20 . Use of the extract according to one of claims 7 to 8 for the production of a preparation according to claims 12 to 15 having an anti-serotonergic, spasmolytic, anticholestatic, choleretic, antiemetic and prokinetic action. 21 . Use of the extract according to one of claims 7 to 8 for the production of a preparation according to claims 12 to 15 to increase vesicular secretion and lipolysis, for the treatment of dyspepsia and for the treatment of IBS (irritable bowel syndrome).
※ AI-Helper는 부적절한 답변을 할 수 있습니다.